NIPH Clinical Trials Search

JRCT ID: jRCT2031200244

Registered date:15/12/2020

A Phase 3 Clinical Study of TS-071 in Paediatric Patients with Type 2 Diabetes Mellitus

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedType 2 diabetes mellitus
Date of first enrollment05/03/2021
Target sample size45
Countries of recruitment
Study typeInterventional
Intervention(s)-Treatment period I: TS-071 2.5 mg or Placebo orally once daily -Treatment period II: TS-071 2.5 mg orally once daily (the dose could be increased to 5 mg)


Primary OutcomeHbA1c
Secondary OutcomeHbA1c, fasting blood glucose, body weight

Key inclusion & exclusion criteria

Age minimum>= 10age old
Age maximum<= 17age old
Include criteria1. Previous diagnosis of type 2 diabetes (outpatient) 2. Males and Females, ages 10 years of age, up to but not including 18 years of age at the time of obtaining informed consent 3. Treatment for type 2 diabetes is applicable to one of the following a. Currently on stable diet and exercise for a minimum of 8 weeks prior to Visit 1 (Week - 4) b. In addition to stable diet and exercise, currently on stable and within the approved dose of metformin for a minimum of 8 weeks prior to Visit 1 (Week - 4) 4. HbA1c >= 7.0% and <= 12.0% measured at Visit 1 (Week - 4) 5. For all HbA1c measured within 8 weeks prior to Visit 1 (Week - 4), the difference from HbA1c measured at Visit 1 (Week - 4) is within 1.0% 6. Fasting plasma glucose >= 126 mg/dL and < 250 mg/dL measured at Visit 1 (Week - 4)
Exclude criteria1. Concurrent diabetes mellitus other than type 2 (type 1 diabetes mellitus, diabetes mellitus due to some specific mechanism/condition other than type 2, or gestational diabetes mellitus) 2. Presense of either: pancreatic island-related autoantibodies [glutamic acid decarboxylase (GAD) antibody, insulinoma-associated protein-2 (IA-2) antibody, zinc transporter 8 (ZnT-8) antibody, insulin autoantibody] 3. Any concurrent endocrine disease other than diabetes mellitus that may have an effect on plasma glucose (such as diseases associated with an abnormality in thyroid function) 4. Current use of the following medications within 8 weeks before Visit 1 (Week - 4) - antidiabetic drugs except for metformin - corticosteroids (excluding topical administration such as external use, nasal drops and eye drops) 5. Patients who developed diabetic ketoacidosis multiple times within 1 year before obtaining informed consent 6. Concurrent severe diabetic microangiopathy (e.g., preproliferative or proliferative diabetic retinopathy, or diabetic neuropathy whose symptoms cannot be adequately controlled in spite of continuous pharmacotherapy, or other complications) 7. Concurrent or history of Diabetic macrovascular disease (cerebrovascular accident, coronary artery disease, peripheral arterial disease) 8. A history of nephrectomy or renal transplantation 9. Any concurrent renal disease requiring aggressive treatment (administration of medications such as adrenocorticosteroids or immunosuppressive agents); 10. Estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2 (after rounding to the nearest integer) consecutively at Visit 1 (Week - 4) 11. A concurrent urinary tract infection or genital infection 12. Patients with an evident urination disorder due to neuropathic bladder, prostatic hypertrophy, or other urinary or bladder disorders 13. ALT or AST > 2 times the upper limit of normal measured at visit 1(Week -4) 14. Patients whose blood pressure was poorly controlled, with a systolic blood pressure (SBP) > 170 mmHg or diastolic blood pressure (DBP) > 100 mmHg at Visit 1 (Week - 4)

Related Information


Public contact
Name Development Headquarters Development Management
Address 3-24,1, Takada, Toshima-Ku, Tokyo Tokyo Japan 170-8633
Telephone +81-3-3985-1118
Affiliation Taisho Pharmaceutical Co., LTD.
Scientific contact
Name Seiji Mita
Address 3-24,1, Takada, Toshima-Ku, Tokyo Tokyo Japan 170-8633
Telephone +81-3-3985-1118
Affiliation Taisho Pharmaceutical Co., LTD.